140 related articles for article (PubMed ID: 32229418)
21. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
22. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report.
McGuire HM; Shklovskaya E; Edwards J; Trevillian PR; McCaughan GW; Bertolino P; McKenzie C; Gourlay R; Gallagher SJ; Fazekas de St Groth B; Hersey P
Cancer Immunol Immunother; 2018 Apr; 67(4):563-573. PubMed ID: 29289977
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
Abdel-Wahab N; Safa H; Abudayyeh A; Johnson DH; Trinh VA; Zobniw CM; Lin H; Wong MK; Abdelrahim M; Gaber AO; Suarez-Almazor ME; Diab A
J Immunother Cancer; 2019 Apr; 7(1):106. PubMed ID: 30992053
[TBL] [Abstract][Full Text] [Related]
24. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
[TBL] [Abstract][Full Text] [Related]
25. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.
Tarhini AA; Moschos SJ; Lin Y; Lin HM; Sander C; Yin Y; Venhaus R; Gajewski TF; Kirkwood JM
Melanoma Res; 2017 Aug; 27(4):342-350. PubMed ID: 28489678
[TBL] [Abstract][Full Text] [Related]
27. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors.
Kamińska-Winciorek G; Cybulska-Stopa B; Lugowska I; Ziobro M; Rutkowski P
Postepy Dermatol Alergol; 2019 Aug; 36(4):382-391. PubMed ID: 31616210
[TBL] [Abstract][Full Text] [Related]
28. Combined immune therapy grade IV dermatitis in metastatic melanoma.
Randhawa M; Archer C; Gaughran G; Miller A; Morey A; Dua D; Yip D
Asia Pac J Clin Oncol; 2019 Aug; 15(4):262-265. PubMed ID: 30809956
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.
Nomura M; Otsuka A; Kondo T; Nagai H; Nonomura Y; Kaku Y; Matsumoto S; Muto M
Cancer Chemother Pharmacol; 2017 Nov; 80(5):999-1004. PubMed ID: 28983657
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Yamazaki N; Uhara H; Fukushima S; Uchi H; Shibagaki N; Kiyohara Y; Tsutsumida A; Namikawa K; Okuyama R; Otsuka Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):969-75. PubMed ID: 26407818
[TBL] [Abstract][Full Text] [Related]
31. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
32. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
33. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
34. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
35. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report.
Ziogas DC; Gkoufa A; Cholongitas E; Diamantopoulos P; Anastasopoulou A; Ascierto PA; Gogas H
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33144335
[TBL] [Abstract][Full Text] [Related]
36. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.
Alouani E; Laparra A; Perret A; Sakkal M; Messayke S; Danlos FX; Ouali K; Hollebecque A; Even C; Ammari S; Baldini C; Champiat S; Besse B; Robert C; Guettier C; Samuel D; Lambotte O; De Martin E; Michot JM
Eur J Cancer; 2023 Nov; 193():113313. PubMed ID: 37748398
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
Afzal MZ; Shirai K
Melanoma Res; 2018 Aug; 28(4):341-347. PubMed ID: 29750753
[TBL] [Abstract][Full Text] [Related]
39. Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab.
Uslu U; Agaimy A; Hundorfean G; Harrer T; Schuler G; Heinzerling L
J Immunother; 2015 Jun; 38(5):212-5. PubMed ID: 25962110
[TBL] [Abstract][Full Text] [Related]
40. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab.
Tanaka R; Fujisawa Y; Sae I; Maruyama H; Ito S; Hasegawa N; Sekine I; Fujimoto M
Jpn J Clin Oncol; 2017 Feb; 47(2):175-178. PubMed ID: 28173241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
